Ryan Jacobs, MD, of the Atrium Health Levine cancer Institute in Charlotte, NC discussed the need for real world data to access treatment efficacy in patients with chronic lymphocytic leukemia. Dr. Jacob also summarizes the results of a retrospective study comparing real world treatment patterns in patients who started on ibrutinib versus acalabrutinib. The data was presented at the 64th ASH Annual Meeting and Exposition (oral abstract 797).
CLL is a rare blood cancer resulting in a build-up of lymphocytes in bone marrow, lymph nodes, and blood. Ibrutinib was the first Bruton tyrosine kinase inhibitor (BTKi) to be approved by the US Food and Drug Administration (FDA) to treat patients with CLL/SLL in 2014 (second line therapy) and 2016 (first line therapy)/. Acalabrutinib, another BTKi, was approved by the FDA in 2017 and 2019 for second line and first line treatment, respectively. Although BTKi treatment patterns have been evaluated in clinical trials, they are poorly understood in the real-world, especially among patients who switch therapy between BTKis.
As Dr. Jacobs explains, they examined pharmacy electronic medical records from academic and non-teaching hospital systems (11/21/2018-4/30/2022) to identify adults with CLL who initiated first line therapy with ibrutinib (n=710) or acalabrutinib (n=373), on or after the date of acalabrutinib approval for CLL (11/21/2019).
The study observed that with a mean follow-up was 17.1 months for the ibrutinib cohort and 12.5 months for the acalabrutinib cohort, the proportion of patients in the ibrutinib cohort who initiated a next or additional treatment was 5.9% compared to 7.5% for acalabrutinib. Furthermore, after adjusting for baseline characteristics, patients treated with acalabrutinib were 89% more likely to start a next or additional treatment than those treated with ibrutinib.
To stay up-to-date on our latest coverage of ASH 2022, visit checkrare.com/diseases/cancers/
12 дек 2022
